Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia

References

• Llovet JM, Ricci S, Mazzaferro V, . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
   PubMed Web of Science ®Google Scholar
• Milella M, Kornblau SM, Estrov Z, . Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001;108:851–859.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, . Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835–844.
   PubMed Web of Science ®Google Scholar
• Crump M. Inhibition of raf kinase in the treatment of acute myeloid leukemia. Curr Pharm Des 2002;8:2243–2248.
   PubMed Web of Science ®Google Scholar
• Illmer T, Thiede C, Fredersdorf A, . Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res 2005;11:3217–3224.
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Desta F, . Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005;19:2232–2240.
   PubMed Web of Science ®Google Scholar
• Zebisch A, Staber PB, Delavar A, . Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 2006;66:3401–3408.
   PubMed Web of Science ®Google Scholar
• Perl AE, Carroll M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr Treat Options Oncol 2007;8: 265–276.
   PubMedGoogle Scholar
• Zebisch A, Czernilofsky AP, Keri G, . Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 2007; 14:601–623.
   PubMed Web of Science ®Google Scholar
• Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008;35: 336–345.
   PubMed Web of Science ®Google Scholar
• Illmer T, Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma 2007;8 (Suppl. 1):S24–S34.
   PubMedGoogle Scholar
• Zhang W, Konopleva M, Shi YX, . Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100:184–198.
   PubMed Web of Science ®Google Scholar
• Padro T, Bieker R, Ruiz S, . Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 2002;16:1302–1310.
   PubMed Web of Science ®Google Scholar
• Bieker R, Padro T, Kramer J, . Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 2003;63:7241–7246.
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Coe S, . The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490–9500.
   PubMed Web of Science ®Google Scholar
• Mori S, Cortes J, Kantarjian H, . Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 2008;49:2246–2255.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology 2006;2006:169–177.
   Google Scholar
• Metzelder S, Wang Y, Wollmer E, . Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia:sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567–6571.
   PubMed Web of Science ®Google Scholar
• Metzelder S, Scholl S, Matthias K, . Compassionate use of sorafenib in relapsed and refractory Flt3-ITD positive acute myeloid leukemia. Blood 2009;114(Suppl. 1): Abstract 2060.
   Google Scholar
• Safaian NN, Czibere A, Bruns I, . Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD + acute myeloid leukemia. Leuk Res 2009;33:348–350.
   PubMed Web of Science ®Google Scholar
• Schroeder T, Saure C, Bruns I, . Clinical efficacy of sorafenib in patients with acute myeloid leukemia (AML) and activating FLT3-mutations. Blood 2009;114(Suppl. 1): Abstract 2057.
   Google Scholar
• Crump M, Hedley D, Kamel-Reid S, . A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010;51:252–260.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, . Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28:1856–1862.
   PubMed Web of Science ®Google Scholar
• Serve H, Wagner R, Sauerland C, . Sorafenib in combination with standard induction and consolidation therapy in elderly AML patients: results from a randomized, placebo-controlled phase II trial. Blood 2010;116(Suppl. 1): Abstract 333.
   Google Scholar